贝瑞基因(000710) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥378,883,684.09, representing a 3.17% increase year-over-year[3] - The net profit attributable to shareholders was a loss of ¥3,187,312.79, a decline of 109.55% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was a loss of ¥3,241,730.19, down 110.24% year-over-year[3] - Net profit for the period was CNY 28,086,414.63, a decrease of 80.91% from CNY 146,827,353.17 in the same period last year[17] - Total comprehensive income for the period was CNY 28,086,414.63, down from CNY 146,827,353.17 in the same period last year[18] - Basic and diluted earnings per share were both CNY 0.0791, down from CNY 0.4288 in the previous period[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,337,361,142.89, an increase of 2.88% from the end of the previous year[3] - Total current assets as of September 30, 2021, amount to ¥2,014,411,380.53, slightly up from ¥2,008,047,115.30 at the end of 2020[12] - Total assets as of September 30, 2021, are ¥3,337,361,142.89, compared to ¥3,243,969,209.24 at the end of 2020[13] - Total liabilities amounted to CNY 826,316,689.95, slightly up from CNY 821,521,396.88 in the prior period[15] - The total liabilities increased to 821,521,396.88 CNY as of September 30, 2021, from 839,473,203.12 CNY at the beginning of the year[26] Cash Flow - Cash flow from operating activities showed a net outflow of ¥94,466,440.00, a decrease of 172.17% compared to the previous year[3] - Cash inflow from operating activities totaled CNY 1,048,917,634.60, compared to CNY 987,780,042.70 in the prior period[20] - Cash outflow from operating activities was CNY 1,143,384,074.60, an increase from CNY 1,022,486,126.72 in the previous period[20] - The net cash flow from operating activities for Q3 2021 was -94,466,440.00 CNY, compared to -34,706,084.02 CNY in Q3 2020, indicating a significant decline[21] - The net cash flow from investing activities was -268,549,931.64 CNY in Q3 2021, a decrease from -69,788,961.38 CNY in the same period last year[21] - Cash inflow from financing activities totaled 264,326,513.85 CNY in Q3 2021, down from 380,845,754.88 CNY in Q3 2020[21] - The net cash flow from financing activities increased to 106,904,431.52 CNY in Q3 2021, compared to 66,344,168.47 CNY in Q3 2020[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 29,393[9] - The largest shareholder, Gao Yang, holds 13.20% of shares, totaling 46,810,572 shares, with 36,945,429 shares pledged[9] Inventory and Borrowings - Inventory increased by 32.19% to ¥238,302,819.30, primarily due to increased reagent procurement[6] - The company's short-term borrowings rose by 73.46% to ¥213,536,104.18, attributed to increased working capital loans[6] - Short-term borrowings increased to ¥213,536,104.18 from ¥123,105,439.03[13] Development and Investments - The construction in progress surged by 3736.97% to ¥143,956,028.47, mainly due to investments in the Fujian Digital Life Industry Park project[6] - The company reported a significant decrease in investment income, with a loss of ¥39,152,709.77, a decline of 2000.24% year-over-year[6] - The company has ongoing development expenditures of ¥18,244,337.65, up from ¥16,787,609.94[13] - The company reported a significant increase in research and development expenses, totaling CNY 91,266,348.09, compared to CNY 89,390,991.77 in the previous period[16] Cash and Equivalents - Cash and cash equivalents decreased to ¥372,310,024.48 from ¥629,308,298.94[12] - The company's cash and cash equivalents at the end of Q3 2021 were 372,310,024.48 CNY, a decrease from 373,666,661.53 CNY at the end of Q3 2020[21] Accounting Changes - The company has implemented a new leasing standard starting January 1, 2021, affecting the financial statements[22] - The company recognized a right-of-use asset of ¥17,541,871.39 as of January 1, 2021, following the new lease accounting standard[27] - Lease liabilities were recorded at ¥17,951,806.24 as of January 1, 2021, indicating the company's commitment under the new lease standard[27] Other Financial Adjustments - Deferred tax assets increased from ¥26,358,767.01 to ¥26,477,937.86, reflecting an adjustment of ¥119,170.85[27] - The company's undistributed profits decreased by ¥290,580.34, from ¥1,052,858,965.48 to ¥1,052,568,385.14[27] - The company's surplus reserves showed a minor adjustment, decreasing by ¥183.66, from ¥77,754,929.46 to ¥77,754,745.80[27] Audit Status - The third quarter report for 2021 was not audited, indicating a potential area for further scrutiny[29]